Literature DB >> 19923250

Novel potassium channel blocker, 4-AP-3-MeOH, inhibits fast potassium channels and restores axonal conduction in injured guinea pig spinal cord white matter.

Wenjing Sun1, Daniel Smith, Yan Fu, Ji-Xin Cheng, Steven Bryn, Richard Borgens, Riyi Shi.   

Abstract

We have demonstrated that 4-aminopyridine-3-methanol (4-AP-3-MeOH), a 4-aminopyridine derivative, significantly restores axonal conduction in stretched spinal cord white-matter strips and shows no preference in restoring large and small axons. This compound is 10 times more potent when compared with 4-AP and other derivatives in restoring axonal conduction. Unlike 4-AP, 4-AP-3-MeOH can restore axonal conduction without changing axonal electrophysiological properties. In addition, we also have confirmed that 4-AP-3-MeOH is indeed an effective blocker of I(A) based on patch-clamp studies using guinea pig dorsal root ganglia cells. Furthermore, we have also provided the critical evidence to confirm the unmasking of potassium channels following mechanical injury. Taken together, our data further supports and implicates the role of potassium channels in conduction loss and its therapeutic value as an effective target for intervention to restore function in spinal cord trauma. Furthermore, due to its high potency and possible low side effect of impacting electrophysiological properties, 4-AP-3-MeOH is perhaps the optimal choice in reversing conduction block in spinal cord injury compared with other derivatives previously reported from this group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923250     DOI: 10.1152/jn.00154.2009

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  26 in total

1.  The effects of paranodal myelin damage on action potential depend on axonal structure.

Authors:  Ehsan Daneshi Kohan; Behnia Shadab Lashkari; Carolyn Jennifer Sparrey
Journal:  Med Biol Eng Comput       Date:  2017-08-03       Impact factor: 2.602

Review 2.  Molecular mechanisms of acrolein-mediated myelin destruction in CNS trauma and disease.

Authors:  R Shi; J C Page; M Tully
Journal:  Free Radic Res       Date:  2015-04-16

3.  Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis.

Authors:  Gary Leung; Wenjing Sun; Sarah Brookes; Daniel Smith; Riyi Shi
Journal:  Exp Neurol       Date:  2010-11-17       Impact factor: 5.330

Review 4.  CNS repair and axon regeneration: Using genetic variation to determine mechanisms.

Authors:  Andrea Tedeschi; Takao Omura; Michael Costigan
Journal:  Exp Neurol       Date:  2016-05-06       Impact factor: 5.330

Review 5.  Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.

Authors:  Riyi Shi; Wenjing Sun
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

Review 6.  Acrolein-mediated injury in nervous system trauma and diseases.

Authors:  Riyi Shi; Todd Rickett; Wenjing Sun
Journal:  Mol Nutr Food Res       Date:  2011-08-08       Impact factor: 5.914

7.  Primary paranode demyelination modulates slowly developing axonal depolarization in a model of axonal injury.

Authors:  Vladislav Volman; Laurel J Ng
Journal:  J Comput Neurosci       Date:  2014-07-03       Impact factor: 1.621

8.  Paranodal myelin damage after acute stretch in Guinea pig spinal cord.

Authors:  Wenjing Sun; Yan Fu; Yuzhou Shi; Ji-Xin Cheng; Peng Cao; Riyi Shi
Journal:  J Neurotrauma       Date:  2011-12-05       Impact factor: 5.269

9.  Effectiveness of 4-Aminopyridine for the Management of Spasticity in Spinal Cord Injury: A Systematic Review.

Authors:  Joshua Wiener; Jane Hsieh; Amanda McIntyre; Robert Teasell
Journal:  Top Spinal Cord Inj Rehabil       Date:  2018-05-03

10.  Cervical spinal demyelination with ethidium bromide impairs respiratory (phrenic) activity and forelimb motor behavior in rats.

Authors:  N L Nichols; A M Punzo; I D Duncan; G S Mitchell; R A Johnson
Journal:  Neuroscience       Date:  2012-11-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.